PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced that they have entered into a research collaboration and license agreement with US-based Eli Lilly and Company (Lilly) focused on the discovery and development of novel peptide drug conjugates (PDCs).
Under the agreement, PeptiDream will utilize its proprietary Peptide Discovery Platform System (PDPS) technology to identify high affinity macrocyclic peptide ligands to Lilly-elected targets of interest, capable of delivering a Lilly conjugated payload to certain cells and tissues of interest to Lilly. PeptiDream will lead peptide discovery and optimization efforts, and Lilly will lead payload discovery and optimization efforts. Lilly will be responsible for all development aspects of any PDC products arising from the collaboration.
The new research collaboration and license agreement builds upon the long collaborative relationship between the companies, with the first collaboration and license agreement in December 2013, followed by the nonexclusive license of PeptiDream
